TrialInvestigational new drugs2021

Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.

David I Quinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.